DE68929419T2 - Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff - Google Patents

Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff

Info

Publication number
DE68929419T2
DE68929419T2 DE68929419T DE68929419T DE68929419T2 DE 68929419 T2 DE68929419 T2 DE 68929419T2 DE 68929419 T DE68929419 T DE 68929419T DE 68929419 T DE68929419 T DE 68929419T DE 68929419 T2 DE68929419 T2 DE 68929419T2
Authority
DE
Germany
Prior art keywords
prototype
isolates
felv
vaccine
faids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929419T
Other languages
English (en)
Other versions
DE68929419D1 (de
Inventor
Edward A Hoover
James I Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Colorado State University Research Foundation
Colorado State University
Original Assignee
Harvard College
Colorado State University Research Foundation
Colorado State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Colorado State University Research Foundation, Colorado State University filed Critical Harvard College
Publication of DE68929419D1 publication Critical patent/DE68929419D1/de
Application granted granted Critical
Publication of DE68929419T2 publication Critical patent/DE68929419T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/819—Viral vaccine for feline species, e.g. cats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE68929419T 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff Expired - Lifetime DE68929419T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28413988A 1988-12-13 1988-12-13

Publications (2)

Publication Number Publication Date
DE68929419D1 DE68929419D1 (de) 2002-08-29
DE68929419T2 true DE68929419T2 (de) 2003-04-03

Family

ID=23088994

Family Applications (2)

Application Number Title Priority Date Filing Date
DE68924478T Expired - Lifetime DE68924478T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.
DE68929419T Expired - Lifetime DE68929419T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE68924478T Expired - Lifetime DE68924478T2 (de) 1988-12-13 1989-12-12 Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoffe.

Country Status (12)

Country Link
US (1) US6042835A (de)
EP (2) EP0699758B1 (de)
JP (1) JP3164351B2 (de)
AT (2) ATE128730T1 (de)
AU (2) AU4616289A (de)
CA (1) CA2005311C (de)
DE (2) DE68924478T2 (de)
DK (1) DK172633B1 (de)
ES (2) ES2179854T3 (de)
GR (1) GR3018587T3 (de)
IE (1) IE74875B1 (de)
NZ (1) NZ231744A (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901778D0 (en) * 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
GB9210337D0 (en) * 1992-05-14 1992-07-01 Univ Court Of The University O Feline leukaemia virus vaccine
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US7674618B2 (en) 2003-09-04 2010-03-09 Medarex, Inc. Expression vector
ZA200608178B (en) * 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
RU2591817C2 (ru) * 2011-07-20 2016-07-20 Мериал Лимитед Рекомбинантная вакцина вируса лейкемии кошек, содержащая оптимизированный ген оболочки вируса лейкемии кошек
EP3583207A4 (de) * 2017-02-16 2020-11-18 Bio-Rad Laboratories, Inc. Neuartige reverse-transkriptasen und verwendungen davon

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034081A (en) * 1973-09-18 1977-07-05 University Of Glasgow Vaccines against feline leukemia
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
GB1486186A (en) * 1973-09-18 1977-09-21 Univ Glasgow Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
US4406885A (en) * 1978-12-28 1983-09-27 Research Corporation Preparation of native oncornavirus envelope subunits and vaccines therefrom
US4264587A (en) * 1979-08-01 1981-04-28 Pedersen Niels C Vaccine for preventing persistent feline leukemia viremia in cats
US4332793A (en) * 1979-12-18 1982-06-01 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4434157A (en) * 1979-12-18 1984-02-28 The Ohio State University Research Foundation Method of recovering cell antigen and preparation of feline leukemia vaccine therefrom
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
EP0156299A3 (de) * 1984-03-26 1987-04-01 Chiron Corporation LTR-modifizierte virale Vakzine
US4794168A (en) * 1984-04-24 1988-12-27 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4663436A (en) * 1984-04-24 1987-05-05 Scripps Clinic And Research Foundation Leukemia-associated virus immunogen, vaccine and assay
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
JP2656521B2 (ja) * 1986-05-30 1997-09-24 ケンブリッジ・バイオサイエンス・コーポレーション ネコ白血病ウイルス抗原の製造法と用途
DE3730599A1 (de) * 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
US5306493A (en) * 1986-10-03 1994-04-26 Miles Inc. FeLV-infected feline cell line
EP0262887A3 (de) * 1986-10-03 1989-07-26 Bayer Corporation FeLV-infizierter Katzenzellstamm
AU1366088A (en) * 1987-01-28 1988-08-24 Ortho Pharmaceutical Corporation Immunosuppressive peptides and methods of use
AU612404B2 (en) * 1987-09-11 1991-07-11 Genentech Inc. Method for increasing the expression of polypeptides in recombinant cell culture

Also Published As

Publication number Publication date
AU3710493A (en) 1993-07-15
ATE221119T1 (de) 2002-08-15
EP0377842A1 (de) 1990-07-18
EP0699758B1 (de) 2002-07-24
GR3018587T3 (en) 1996-04-30
NZ231744A (en) 1993-01-27
DE68924478D1 (de) 1995-11-09
AU661134B2 (en) 1995-07-13
ES2179854T3 (es) 2003-02-01
EP0699758A1 (de) 1996-03-06
ES2084596T3 (es) 1996-05-16
DK631089D0 (da) 1989-12-13
IE74875B1 (en) 1997-08-13
DE68924478T2 (de) 1996-03-07
DK631089A (da) 1990-06-14
DE68929419D1 (de) 2002-08-29
JPH03117490A (ja) 1991-05-20
US6042835A (en) 2000-03-28
DK172633B1 (da) 1999-03-22
AU4616289A (en) 1990-06-21
IE960745L (en) 1990-06-13
CA2005311C (en) 2006-05-30
IE893974L (en) 1990-06-13
EP0377842B1 (de) 1995-10-04
ATE128730T1 (de) 1995-10-15
JP3164351B2 (ja) 2001-05-08
CA2005311A1 (en) 1990-06-13

Similar Documents

Publication Publication Date Title
EP0584348A4 (en) Genetic vaccine for immunodeficiency viruses
SE9102975L (sv) Bakterofag och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
ATE257175T1 (de) Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
NZ224581A (en) Hiv-2 peptide, aids vaccine
ATE47725T1 (de) Zum hervorrufen von aids geeigneter retrovirus vom typ hiv-2, sowie seine antigen- und nukleinsaeure-bestandteile.
ATE114711T1 (de) Zellinie, die virale aids-antigene produziert, ohne infektiöse viruspartikel zu produzieren.
NZ333431A (en) Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
DE68929419D1 (de) Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
NZ213155A (en) Molecular clones of the genome of hiv (htlv-iii)
ATE91902T1 (de) Hundecoronavirus-impfstoff.
SG55095A1 (en) Viruses and their use as a vaccine against feline infectious peritonitis virus disease
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
DE68924155D1 (de) Verfahren zur herstellung von natürlichem hiv-glykoprotein 160.
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
ATE103934T1 (de) Impfstoff bestehend aus einem virusvektor und rekombinanten-dns, die das p25-protein vom aids- virus kodieren.
EP0997529A3 (de) Fiv-141 stamm vom immunschwächevirus der Katze und dessen Verwendungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition